Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
26 févr. 2024 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology...
Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering
22 juin 2023 16h15 HE
|
Daxor Corporation
Oak Ridge, TN, June 22, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Maxim Group LLC (“Maxim”), as...
Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
17 févr. 2022 08h00 HE
|
Daxor Corporation
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors
21 janv. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD,...
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
06 janv. 2022 08h00 HE
|
Daxor Corporation
Oak Ridge, TN, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh...
DAXOR ANNOUNCES KEY MILESTONES ACHIEVED FOR MULTICENTER BVA-100® STUDY IN HOSPITALIZED PATIENTS WITH COVID-19
05 janv. 2022 08h00 HE
|
Daxor Corporation
Patient Enrollment Complete and Data Analysis Commences with Daxor’s Blood Volume Analysis Technology Oak Ridge, TN, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the...
New Research Demonstrates Clinical Utility of Daxor Corporation Blood Volume (BVA-100®) Diagnostic in Neurocritical Care
09 nov. 2021 08h00 HE
|
Daxor Corporation
Data Presented at the NeuroCritical Care Society 19th Annual Meeting 2021 Data Highlight Daxor’s Diagnostic Changes Care in 69% of Patients With Non-Traumatic Subarachnoid Hemorrhage (nSAH) NEW...
Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021
30 août 2021 08h30 HE
|
Daxor Corporation
Company forecasts further increase in sales driven by new distributor agreements Oak Ridge, TN, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume...
DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONS
22 juil. 2021 08h30 HE
|
Daxor Corporation
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has signed a non-government...
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
13 mai 2021 08h30 HE
|
Daxor Corporation
NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in...